Eitaro Kodani

Dr. Eitaro Kodani

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
EKEitaro Kodani
Eitaro Kodani
HAHirotsugu Atarashi
Hirotsugu Atarashi
HIHiroshi Inoue
Hiroshi Inoue
KOKen Okumura
Ken Okumura
TYTakeshi Yamashita
Takeshi Yamashita
KKK. Kumagai
K. Kumagai
Background: To clarify the influence of hypertension and blood pressure ( BP ) control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation, a post hoc analysis of the J‐ RHYTHM Registry was performed. Methods and Results: A consecutive series of outpatients with atrial fibrillation was enrolled from 158 institutions. Of 7937 patients, 7406 with nonvalvular atrial fibrillation (70.8% men, 69.8±10.0 years) were followed for 2 years or until an event occurred. Hypertension was defined as a systolic BP ≥140 mm Hg, a diastolic BP ≥90 mm Hg, a history of hypertension, and/or antihypertensive drug use. Hypertension was an independent risk factor for major hemorrhage (hazard ratio 1.52, 95% CI 1.05–2.21, P =0.027) but not for thromboembolism (hazard ratio 1.05, 95% CI 0.73–1.52, P =0.787). When patients were divided into quartiles according to their systolic BP at the time closest to the event or at the end of follow‐up (Q1, <114; Q2, 114–125; Q3, 126–135; and Q4, ≥136 mm Hg), odds ratios for both events were significantly higher in Q4 than in Q1 (thromboembolism, odds ratio 2.88, 95% CI 1.75–4.74, P <0.001; major hemorrhage, odds ratio 1.61, 95% CI 1.02–2.53, P =0.041) after adjustment for components of CHA 2 DS 2 ‐ VAS c score, warfarin use, and antiplatelet use. A systolic BP of ≥136 mm Hg was an independent risk factor for thromboembolism and major hemorrhage. Conclusions: BP control appears to be more important than a history of hypertension and baseline BP values at preventing thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation. Clinical Trial Registration: URL : http://www.umin.ac.jp/ctr . Unique identifier: UMIN 000001569.

1 July 2016 in The American Journal of Cardiology
Verified
Journal Article
Closed access
HIHiroshi Inoue
Hiroshi Inoue
EKEitaro Kodani
Eitaro Kodani
HAHirotsugu Atarashi
Hirotsugu Atarashi
KOKen Okumura
Ken Okumura
TYTakeshi Yamashita
Takeshi Yamashita
HOHideki Origasa
Hideki Origasa

1 September 2017 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
PDF file
EKEitaro Kodani
Eitaro Kodani
HAHirotsugu Atarashi
Hirotsugu Atarashi
HIHiroshi Inoue
Hiroshi Inoue
KOKen Okumura
Ken Okumura
TYTakeshi Yamashita
Takeshi Yamashita
HOHideki Origasa
Hideki Origasa
To clarify the influence of renal function on adverse outcomes in patients with non-valvular atrial fibrillation (NVAF), a post hoc analysis of the J-RHYTHM Registry was performed. A consecutive series of outpatients with atrial fibrillation (AF) were enrolled from 158 institutions and followed for 2 years or until the occurrence of an event. Among 7406 patients with non-valvular AF, 6052 patients (69.8 ± 10.0 years, 71.2% men) with creatinine clearance (CrCl) value at baseline were divided into four groups according to CrCl level (<30, 30–49.9, 50–79.9, and ≥80 mL/min). Patients with CrCl <80 mL/min showed increased incidence of thromboembolism, major haemorrhage, all-cause and cardiovascular death, and composite events as compared with patients with CrCl ≥80 mL/min. After adjustment for multiple confounders, lower CrCl values emerged as independent predictors for thromboembolism [CrCl 30–49.9, hazard ratio (HR) 2.27, 95% confidence interval (CI) 1.09–4.72, P = 0.029; and CrCl 50–79.9, HR 1.99, 95% CI 1.07–3.72, P = 0.030] and all-cause death (CrCl <30, HR 6.44, 95% CI 3.03–13.7, P < 0.001; and CrCl 30–49.9, HR 3.14, 95% CI 1.54–6.41, P = 0.002), with CrCl ≥80 mL/min serving as a reference, whereas not for major haemorrhage. Warfarin treatment was associated with lower rates of composite events in patients with lower CrCl values of <80 mL/min. Renal impairment was an independent predictor of adverse clinical outcomes except for major haemorrhage in Japanese patients with non-valvular AF. Warfarin was associated with lower rates of composite events in patients with lower CrCl values. http://www.umin.ac.jp/ctr/. Unique identifier: UMIN000001569.

1 January 2015 in Circulation Journal
Verified
Journal Article
Open access
PDF file
EKEitaro Kodani
Eitaro Kodani
HAHirotsugu Atarashi
Hirotsugu Atarashi
HIHiroshi Inoue
Hiroshi Inoue
KOKen Okumura
Ken Okumura
TYTakeshi Yamashita
Takeshi Yamashita
OIon behalf of the J-RHYTHM Registry Investigators
on behalf of the J-RHYTHM Registry Investigators
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

1 March 2020 in International Journal of Cardiology
Verified
Journal Article
Open access
EKEitaro Kodani
Eitaro Kodani
HIHiroshi Inoue
Hiroshi Inoue
HAHirotsugu Atarashi
Hirotsugu Atarashi
KOKen Okumura
Ken Okumura
TYTakeshi Yamashita
Takeshi Yamashita
HOHideki Origasa
Hideki Origasa
To clarify the influence of hemoglobin concentration and platelet count on adverse outcomes of Japanese patients with non-valvular atrial fibrillation (NVAF), a post hoc analysis of the J-RHYTHM Registry was performed. A consecutive series of outpatients with atrial fibrillation were enrolled from 158 institutions and followed up for 2 years or until an event occurred (thromboembolism, major hemorrhage, or all-cause death). Among 7406 patients with NVAF, 6536 with complete blood count data (69.8 ± 9.9 years, 71.0% men) were divided into 4 groups according to the baseline hemoglobin level (<10.0, 10.0-11.9, 12.0-13.9, and ≥14.0 g/dL) or platelet count (<10.0, 10.0-19.9, 20.0-29.9, and ≥30.0 × 104/μL). Incidence rates of major hemorrhage (p = 0.004 for trend), all-cause death (p < 0.001 for trend), and composite events (p < 0.001 for trend) increased as hemoglobin levels decreased, and composite events (p = 0.045 for trend) increased as platelet counts decreased. After adjusting for multiple confounders, the incidence of all-cause death and composite events was higher with hemoglobin levels <12.0 g/dL than a hemoglobin level ≥14.0 g/dL. In contrast, platelet count was not associated with any events. This was also true when multivariate analysis was performed using the stepwise forward method. A low hemoglobin level (<12.0 g/dL) was an independent risk factor for all-cause death and composite events in Japanese patients with NVAF. However, platelet count did not impact outcomes. http://www.umin.ac.jp/ctr/ (unique identifier: UMIN000001569).

1 January 2015 in Circulation Journal
Verified
Journal Article
Closed access
PDF file
EKEitaro Kodani
Eitaro Kodani
HAHirotsugu Atarashi
Hirotsugu Atarashi
HIHiroshi Inoue
Hiroshi Inoue
KOKen Okumura
Ken Okumura
TYTakeshi Yamashita
Takeshi Yamashita
OIon behalf of the J-RHYTHM Registry Investigators
on behalf of the J-RHYTHM Registry Investigators
Background:To clarify the effects of warfarin therapy in very old patients with non-valvular atrial fibrillation (NVAF), a post-hoc analysis was performed using the data of the J-RHYTHM Registry.Methods and Results:A consecutive series of AF outpatients was enrolled from 158 institutions. Of 7,937 patients, 7,406 with NVAF (men, 70.8%; 69.8±10.0 years) were followed for 2 years or until an event occurred. Patients were divided into 3 age groups (<70, 70–84, and ≥85 years) and 5 subgroups according to international normalized ratio (INR; <1.6, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0). Prevalence of female sex, permanent AF, hypertension, coronary artery disease, heart failure, and history of ischemic stroke/transient ischemic attack was higher in the older groups. In the oldest group, 79.7% of patients received warfarin and their time in therapeutic range, using the Japanese target INR of 1.6–2.6, was 67.1%. Rate of thromboembolic events was lower in the age groups <70 and 70–84 years (P=0.027 and P<0.001, respectively) for patients receiving warfarin compared with those who were not. In the oldest group, the rate of thromboembolism plus major hemorrhage was lower at INR 1.6–2.59.Conclusions:Warfarin could have beneficial effects even in very old NVAF patients if INR is kept between 1.6 and 2.59. (Circ J 2015; 79: 2345–2352)